Avid Bioservices Reports Financial Results for Fourth Quarter and Fiscal Year Ended April 30, 2024

-- Signed $30 Million in Net New Business Resulting in Backlog of$193 Million -- TUSTIN, Calif., July 02, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced financial results for the fourth quarter and year ended April 30, 2024. "Supporting our optimism, i ...